SI1734959T1 - Spojine za zdravljenje shizofrenije in/ali glukoregulatornih nenormalnosti - Google Patents
Spojine za zdravljenje shizofrenije in/ali glukoregulatornih nenormalnostiInfo
- Publication number
- SI1734959T1 SI1734959T1 SI200530883T SI200530883T SI1734959T1 SI 1734959 T1 SI1734959 T1 SI 1734959T1 SI 200530883 T SI200530883 T SI 200530883T SI 200530883 T SI200530883 T SI 200530883T SI 1734959 T1 SI1734959 T1 SI 1734959T1
- Authority
- SI
- Slovenia
- Prior art keywords
- compounds
- treating schizophrenia
- glucoregulatory
- abnormalities
- glucoregulatory abnormalities
- Prior art date
Links
- 230000005856 abnormality Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 230000002039 glucoregulatory effect Effects 0.000 title 1
- 201000000980 schizophrenia Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US55845104P | 2004-04-01 | 2004-04-01 | |
| EP05732721A EP1734959B1 (en) | 2004-04-01 | 2005-04-01 | Compounds for treating schizophrenia and/or glucoregulatory abnormalities |
| PCT/US2005/011107 WO2005097122A2 (en) | 2004-04-01 | 2005-04-01 | Method of treating schizophrenia and/or glucoregulatory abnormalities |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI1734959T1 true SI1734959T1 (sl) | 2010-02-26 |
Family
ID=34978926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI200530883T SI1734959T1 (sl) | 2004-04-01 | 2005-04-01 | Spojine za zdravljenje shizofrenije in/ali glukoregulatornih nenormalnosti |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US20070129403A1 (https=) |
| EP (2) | EP1734959B1 (https=) |
| JP (1) | JP2007531730A (https=) |
| KR (1) | KR20070010161A (https=) |
| CN (1) | CN1946399A (https=) |
| AR (1) | AR048197A1 (https=) |
| AT (1) | ATE446754T1 (https=) |
| AU (1) | AU2005231446A1 (https=) |
| BR (1) | BRPI0509512A (https=) |
| CA (1) | CA2561162A1 (https=) |
| CL (1) | CL2009001605A1 (https=) |
| CY (1) | CY1109734T1 (https=) |
| DE (1) | DE602005017373D1 (https=) |
| DK (1) | DK1734959T3 (https=) |
| DO (1) | DOP2005000050A (https=) |
| ES (1) | ES2334241T3 (https=) |
| GT (1) | GT200500063A (https=) |
| IL (1) | IL178168A0 (https=) |
| MX (1) | MXPA06011222A (https=) |
| PA (1) | PA8628601A1 (https=) |
| PL (1) | PL1734959T3 (https=) |
| PT (1) | PT1734959E (https=) |
| SI (1) | SI1734959T1 (https=) |
| SV (1) | SV2006002069A (https=) |
| TW (1) | TW200602040A (https=) |
| WO (1) | WO2005097122A2 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY145694A (en) | 2005-04-11 | 2012-03-30 | Xenon Pharmaceuticals Inc | Spiroheterocyclic compounds and their uses as therapeutic agents |
| MY144968A (en) | 2005-04-11 | 2011-11-30 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their uses as therapeutic agents |
| AR063280A1 (es) | 2006-10-12 | 2009-01-21 | Xenon Pharmaceuticals Inc | Uso de compuestos de espiro-oxindol como agentes terapeuticos |
| JP2010506853A (ja) * | 2006-10-12 | 2010-03-04 | ゼノン・ファーマシューティカルズ・インコーポレイテッド | 疼痛などのナトリウムチャネル媒介性の疾患の処置のための、スピロ（［３，２−フロ］ピリジン−３，３’−インドール）−２’（１’ｈ）−オン誘導体および関連化合物 |
| CN105218565A (zh) | 2008-10-17 | 2016-01-06 | 泽农医药公司 | 螺羟吲哚化合物及其作为治疗剂的用途 |
| CA2741024A1 (en) | 2008-10-17 | 2010-04-22 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
| WO2010068750A2 (en) * | 2008-12-11 | 2010-06-17 | Board Of Trustees Of Leland Stanford Junior University | Compositons and method for treatment of mood and cognitive impairments |
| AU2010256541B2 (en) * | 2009-06-03 | 2016-03-10 | Marquette University | Modulation of KCNQ potassium channel activity for treatment of psychiatric disorders and the symptoms thereof |
| AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
| MX2012004373A (es) | 2009-10-14 | 2012-06-28 | Xenon Pharmaceuticals Inc | Metodos sinteticos para compuestos espiro-oxoindol. |
| CA2788440A1 (en) | 2010-02-26 | 2011-09-01 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| CN103512972A (zh) * | 2013-07-29 | 2014-01-15 | 上海交通大学 | 精神分裂症的生物标志物及其使用方法和应用 |
| TW201636017A (zh) | 2015-02-05 | 2016-10-16 | 梯瓦製藥國際有限責任公司 | 以螺吲哚酮化合物之局部調配物治療帶狀疱疹後遺神經痛之方法 |
| KR101759122B1 (ko) | 2015-08-07 | 2017-07-18 | 계명대학교 산학협력단 | 오렉신 a를 함유하는 당뇨병 치료용 약학 조성물 |
| ES3025836T3 (en) | 2016-08-24 | 2025-06-09 | Prilenia Neurotherapeutics Ltd | Use of pridopidine for treating functional decline |
| AU2020242978B2 (en) | 2019-03-19 | 2025-10-02 | Cambridge Cognition Limited | Method and uses of diagnosing and recommending treatment for a psychotic disorder |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4880822A (en) * | 1987-04-24 | 1989-11-14 | Hoechst-Roussel Pharmaceuticals, Inc. | N-(pyridinyl)-1H-indol-1-amines |
| US4970218A (en) | 1987-04-24 | 1990-11-13 | Hoechst-Roussel Pharmaceuticals Inc. | N-(pyridinyl)-1H-indol-1-amines |
| ATE115143T1 (de) * | 1987-04-24 | 1994-12-15 | Hoechst Roussel Pharma | N-(pyridinyl)-1h-indol-1-amine, verfahren zu deren herstellung und ihre verwendung als arzneimittel. |
| US5102891A (en) * | 1990-07-23 | 1992-04-07 | Hoechst-Roussel Pharmaceuticals Inc. | 1-(substituted pyridinylamino)-1H-indol-5-yl substituted carbamates |
| US5214038A (en) * | 1991-04-15 | 1993-05-25 | Hoechst-Roussel Pharmaceuticals Inc. | 1-(pyrido[3,4-b]-1,4-oxazinyl-4-yl)-1H-indoles and intermediates for the preparation thereof |
| US5356910A (en) * | 1993-07-19 | 1994-10-18 | Hoechst-Roussel Pharmaceuticals Inc. | Use of N-(pyridinyl)-1H-indol-1-amines for the treatment of obsessive-compulsive disorder |
| NZ312577A (en) * | 1995-07-27 | 1999-08-30 | Hoechst Marion Roussel Inc | Use of optionally substituted n-(pyrrol-1-yl)-pyridinamines as anticonvulsant agents |
| AU727775B2 (en) | 1996-01-17 | 2000-12-21 | Novo Nordisk A/S | Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use |
| IL128332A0 (en) | 1996-08-30 | 2000-01-31 | Novo Nordisk As | GLP-1 derivatives |
| DE19726167B4 (de) | 1997-06-20 | 2008-01-24 | Sanofi-Aventis Deutschland Gmbh | Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung |
| PL338013A1 (en) | 1997-07-16 | 2000-09-25 | Novo Nordisk As | Derivatives of condensed 1,2,4-thiadiazine, their production and application |
| GB0119435D0 (en) * | 2001-02-15 | 2001-10-03 | Aventis Pharm Prod Inc | Method of treating of demyelinating diseases or conditions |
-
2005
- 2005-03-22 GT GT200500063A patent/GT200500063A/es unknown
- 2005-03-30 DO DO2005000050A patent/DOP2005000050A/es unknown
- 2005-03-31 AR ARP050101275A patent/AR048197A1/es not_active Application Discontinuation
- 2005-04-01 TW TW094110410A patent/TW200602040A/zh unknown
- 2005-04-01 WO PCT/US2005/011107 patent/WO2005097122A2/en not_active Ceased
- 2005-04-01 SV SV2005002069A patent/SV2006002069A/es unknown
- 2005-04-01 AU AU2005231446A patent/AU2005231446A1/en not_active Abandoned
- 2005-04-01 KR KR1020067022972A patent/KR20070010161A/ko not_active Ceased
- 2005-04-01 SI SI200530883T patent/SI1734959T1/sl unknown
- 2005-04-01 MX MXPA06011222A patent/MXPA06011222A/es active IP Right Grant
- 2005-04-01 ES ES05732721T patent/ES2334241T3/es not_active Expired - Lifetime
- 2005-04-01 CN CNA2005800121147A patent/CN1946399A/zh active Pending
- 2005-04-01 DE DE602005017373T patent/DE602005017373D1/de not_active Expired - Lifetime
- 2005-04-01 PT PT05732721T patent/PT1734959E/pt unknown
- 2005-04-01 PL PL05732721T patent/PL1734959T3/pl unknown
- 2005-04-01 DK DK05732721.5T patent/DK1734959T3/da active
- 2005-04-01 CA CA002561162A patent/CA2561162A1/en not_active Abandoned
- 2005-04-01 EP EP05732721A patent/EP1734959B1/en not_active Expired - Lifetime
- 2005-04-01 JP JP2007506313A patent/JP2007531730A/ja not_active Abandoned
- 2005-04-01 BR BRPI0509512-3A patent/BRPI0509512A/pt not_active IP Right Cessation
- 2005-04-01 EP EP09012248A patent/EP2138176A1/en not_active Withdrawn
- 2005-04-01 AT AT05732721T patent/ATE446754T1/de not_active IP Right Cessation
- 2005-04-01 PA PA20058628601A patent/PA8628601A1/es unknown
-
2006
- 2006-09-18 IL IL178168A patent/IL178168A0/en unknown
- 2006-09-29 US US11/536,808 patent/US20070129403A1/en not_active Abandoned
-
2009
- 2009-07-17 CL CL2009001605A patent/CL2009001605A1/es unknown
-
2010
- 2010-01-11 CY CY20101100028T patent/CY1109734T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL178168A0 (en) | 2006-12-31 |
| GT200500063A (es) | 2005-10-14 |
| MXPA06011222A (es) | 2007-01-16 |
| CL2009001605A1 (es) | 2009-11-27 |
| SV2006002069A (es) | 2006-05-24 |
| JP2007531730A (ja) | 2007-11-08 |
| AR048197A1 (es) | 2006-04-05 |
| EP2138176A1 (en) | 2009-12-30 |
| CY1109734T1 (el) | 2014-09-10 |
| DE602005017373D1 (de) | 2009-12-10 |
| DK1734959T3 (da) | 2010-03-08 |
| BRPI0509512A (pt) | 2007-09-11 |
| CN1946399A (zh) | 2007-04-11 |
| ES2334241T3 (es) | 2010-03-08 |
| EP1734959A2 (en) | 2006-12-27 |
| PA8628601A1 (es) | 2006-05-16 |
| ATE446754T1 (de) | 2009-11-15 |
| TW200602040A (en) | 2006-01-16 |
| AU2005231446A1 (en) | 2005-10-20 |
| PT1734959E (pt) | 2009-12-24 |
| DOP2005000050A (es) | 2005-11-30 |
| WO2005097122A3 (en) | 2006-02-02 |
| PL1734959T3 (pl) | 2010-03-31 |
| WO2005097122A2 (en) | 2005-10-20 |
| US20070129403A1 (en) | 2007-06-07 |
| KR20070010161A (ko) | 2007-01-22 |
| EP1734959B1 (en) | 2009-10-28 |
| CA2561162A1 (en) | 2005-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL190991A0 (en) | Agents for treating cardiopathy | |
| LT2803366T (lt) | Kompozicijos, skirtos su oksalatu susijusių ligų gydymui arba prevencijai | |
| IL187238A0 (en) | Compositions and methods for treating hyperproliferative epidermal diseases | |
| IL191118B (en) | Ritoxy Mav for use in the treatment of joint damage | |
| EP1959929A4 (en) | COMPOSITIONS AND METHODS FOR TREATING DERMATOLOGICAL SUFFERING | |
| EP1709900A4 (en) | ENDOSCOPE TREATMENT SYSTEM | |
| IL183889A0 (en) | Treatment method | |
| PL1734959T3 (pl) | Związki do leczenia schizofrenii i/lub nieprawidłowości w gospodarce glukozowej | |
| ZA200800006B (en) | Composition for treating skin lesions | |
| ZA200708033B (en) | Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia | |
| EP1827491A4 (en) | TREATMENT OF MULTIPLE SCLEROSIS | |
| EP1712195A4 (en) | TREATMENT DEVICE FOR AN ENDOSCOPE | |
| EP1736093A4 (en) | ENDOSCOPIC TREATMENT SYSTEM | |
| EP1883405A4 (en) | METHODS OF TREATING NEPHROLITHIASIS | |
| EP1842498A4 (en) | TREATMENT DEVICE FOR AN ENDOSCOPE | |
| GB2430002B (en) | Well treatment | |
| GB0426141D0 (en) | Treatment | |
| GB0511769D0 (en) | Treatment | |
| GB0525540D0 (en) | New treatment | |
| GB0424085D0 (en) | Well treatment | |
| SI1535612T1 (sl) | Zdravljenje hiperurikemije | |
| GB0505203D0 (en) | Skin composition treatment | |
| IL184869A0 (en) | Device for treating skin | |
| GB2433935B (en) | Compounds for treating diabetes and related disorders | |
| GB0422535D0 (en) | Composition for treating a skin disorder |